February 06, 2026
1 min read
The FDA announced it planned to restrict use of GLP-1 active pharmaceutical ingredients in non-FDA-approved drugs, including those from Hims & Hers and other compounding pharmacies.
“These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety or efficacy,” Martin A. Makary, MD, MPH, FDA Commissioner, wrote in a press release.
The FDA plans to restrict the use of GLP-1 active pharmaceutical ingredients in non-FDA-approved drugs, according to a press release.
The FDA also intends to act against direct-to-consumer advertising about non-FDA-approved compounded products.
“Companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA,” Makary wrote. “They also cannot state compounded drugs use the same active ingredient as the FDA-approved drugs or that compounded drugs are clinically proven to produce results for the patient.”
Sources/Disclosures
Source:
Press Release
Reference:
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply